Dr Christopher Rowe

Dr Christopher Rowe

Conjoint Lecturer

School of Medicine and Public Health

Career Summary

Biography

I am an Adult Endocrinologist at the John Hunter Hospital and early-career clinician-researcher at the University of Newcastle and the Hunter Medical Research Institute. 

My primary area of research relates to thyroid nodules and thyroid cancer, although I am active across a wide range of projects in diabetes, pregnancy and endocrinology in the basic and clinical spheres. 

My current doctoral studies through the University of Newcastle School of Medicine and Public Health are investigating new diagnostic and therapetic targets for thyroid cancer.  In particular, our group is examining the utility of the TSH receptor as a specific theranostic marker for drug delivery, in collaboration with the John Hunter Hospital Thyroid Cancer Multidisciplinary Team, the Hunter Cancer Biobank and Pathology North (Hunter).  I am also collaborating with Professor Hubert Hondermarck in the School of Biomedical Sciences and Pharmacy to study the role of neurotrophins as biomarkers and therapeutic targets in thyroid malignancy.

I am active in a number of clinical research projects studying the impact of visceral fat on insulin resistance in Type 1 and Type 2 Diabetes, and therapeutic strategies to mitigate this.

I am a current recipient of a Clinical Research Fellowship (Hunter New England Local Health District), and my recent research has been supported by the Hunter Cancer Research Alliance, Avant Mutual Group, the University of Newcastle, and the John Hunter Hospital Charitable Trust. 


Qualifications

  • Bachelor of Medicine, Bachelor of Surgery (Hons), University of New South Wales
  • Bachelor of Science (Medicine), University of New South Wales

Keywords

  • Diabetes Mellitus
  • endocrinology
  • insulin resistance
  • pregnancy
  • thyroid

Fields of Research

Code Description Percentage
110306 Endocrinology 60
110901 Autonomic Nervous System 20
110102 Medical Biochemistry: Carbohydrates 20

Awards

Prize

Year Award
2016 Australian Diabetes Society Travel Grant (Outstanding Abstract)
Australian Diabetes Society (ADS)
2016 Australasian Diabetes in Pregnancy Society Travel Grant (Outstanding Abstract)
Australian Diabetes in Pregnancy Society (ADIPS)
2015 Endocrine Society (USA) Travel Grant (Outstanding Abstract)
The Endocrine Society
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (8 outputs)

Year Citation Altmetrics Link
2018 Gao F, Griffin N, Faulkner S, Rowe CW, Williams L, Roselli S, et al., 'The neurotrophic tyrosine kinase receptor TrkA and its ligand NGF are increased in squamous cell carcinomas of the lung', SCIENTIFIC REPORTS, 8 (2018) [C1]
DOI 10.1038/s41598-018-26408-2
Citations Scopus - 2Web of Science - 1
Co-authors Marjorie Walker, Sam Faulkner, Hubert Hondermarck, Rick Thorne, Phillip Jobling
2018 Rowe CW, Putt E, Brentnall O, Gebuehr A, Allabyrne J, Woods A, Wynne K, 'An intravenous insulin protocol designed for pregnancy reduces neonatal hypoglycaemia following betamethasone administration in women with gestational diabetes.', Diabet Med, (2018)
DOI 10.1111/dme.13864
2018 Faulkner S, Jobling P, Rowe CW, Rodrigues Oliveira SM, Roselli S, Thorne RF, et al., 'Neurotrophin Receptors TrkA, p75

© 2018 American Society for Investigative Pathology Neurotrophin receptors are emerging targets in oncology, but their clinicopathologic significance in thyroid cancer is unclear.... [more]

© 2018 American Society for Investigative Pathology Neurotrophin receptors are emerging targets in oncology, but their clinicopathologic significance in thyroid cancer is unclear. In this study, the neurotrophin tyrosine receptor kinase TrkA (also called NTRK1), the common neurotrophin receptor p75NTR, and the proneurotrophin receptor sortilin were analyzed with immunohistochemistry in a cohort of thyroid cancers (n = 128) and compared with adenomas and normal thyroid tissues (n = 62). TrkA was detected in 20% of thyroid cancers, compared with none of the benign samples (P = 0.0007). TrkA expression was independent of histologic subtypes but associated with lymph node metastasis (P = 0.0148), suggesting the involvement of TrkA in tumor invasiveness. Nerves in the tumor microenvironment were positive for TrkA. p75NTR was overexpressed in anaplastic thyroid cancers compared with papillary and follicular subtypes (P < 0.0001). Sortilin was overexpressed in thyroid cancers compared with benign thyroid tissues (P < 0.0001). Neurotrophin receptor expression was confirmed in a panel of thyroid cancer cell lines at the mRNA and protein levels. Functional investigations using the anaplastic thyroid cancer cell line CAL-62 found that siRNA against TrkA, p75NTR, and sortilin decreased cell survival and cell migration through decreased SRC and ERK activation. Together, these data reveal TrkA, p75NTR, and sortilin as potential therapeutic targets in thyroid cancer.

DOI 10.1016/j.ajpath.2017.09.008
Citations Scopus - 5Web of Science - 4
Co-authors Marjorie Walker, Christopher Oldmeadow, Phillip Jobling, Rick Thorne, Hubert Hondermarck, Xu Zhang, Chenchen Jiang, Sam Faulkner, John Attia
2018 Rowe CW, Arthurs S, O'Neill CJ, Hawthorne J, Carroll R, Wynne K, Bendinelli C, 'High-dose preoperative cholecalciferol to prevent post-thyroidectomy hypocalcaemia: a randomized, double-blind placebo-controlled trial.', Clin Endocrinol (Oxf), (2018)
DOI 10.1111/cen.13897
2017 Rowe CW, Paul JW, Gedye C, Tolosa JM, Bendinelli C, McGrath S, Smith R, 'Targeting the TSH receptor in thyroid cancer', Endocrine-Related Cancer, 24 R191-R202 (2017) [C1]

© 2017 Society for Endocrinology Printed in Great Britain. Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The exis... [more]

© 2017 Society for Endocrinology Printed in Great Britain. Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The existing paradigm of therapeutic thyroid-stimulating hormone receptor (TSHR) targeting in the post-surgical management of differentiated thyroid cancer using levothyroxine and recombinant human thyroid-stimulating hormone (TSH) is well understood. However, in an era of personalized medicine, and with an increasing awareness of the risk profile of longstanding pharmacological hyperthyroidism, it is imperative clinicians understand the molecular basis and magnitude of benefit for individual patients. Furthermore, TSHR has been recently re-conceived as a selective target for residual metastatic thyroid cancer, with pilot data demonstrating effective targeting of nanoparticles to thyroid cancers using this receptor as a target. This review examines the evidence for TSHR signaling as an oncogenic pathway and assesses the evidence for ongoing TSHR expression in thyroid cancer metastases. Priorities for further research are highlighted.

DOI 10.1530/ERC-17-0010
Citations Scopus - 2Web of Science - 2
Co-authors Roger Smith, Craig Gedye, Jonathan Paul
2017 Rowe CW, Haider AS, Viswanathan D, Jones M, Attia J, Wynne K, Acharya S, 'Insulin resistance correlates with maculopathy and severity of retinopathy in young adults with Type 1 Diabetes Mellitus', Diabetes Research and Clinical Practice, 131 154-160 (2017) [C1]

© 2017 Elsevier B.V. Aims To assess the relationship between insulin resistance (IR), retinopathy and maculopathy in young adults with Type 1 diabetes mellitus. Methods A cross-se... [more]

© 2017 Elsevier B.V. Aims To assess the relationship between insulin resistance (IR), retinopathy and maculopathy in young adults with Type 1 diabetes mellitus. Methods A cross-sectional study at a regional Australian tertiary hospital. Retinal pathology, assessed by colour fundus photography, was correlated with two surrogate measures of IR: estimated Glucose Disposal Rate (eGDR) and Insulin Sensitivity Score (ISS), where lower scores reflect greater IR. Results 107 patients were recruited, with mean age 24.7¿years, 53% male, and mean duration of disease 10.8¿years. Mean eGDR scores (5.6¿vs 8.0 p¿<¿0.001) and ISS (4.7¿vs 7.9, p¿<¿0.001) were lower in subjects having at least moderate non-proliferative diabetic retinopathy (NPDR; relative to nil/mild-NPDR). Similarly, mean eGDR (4.2¿vs 6.2, p¿=¿0.001) and ISS (3.8¿vs 6.1, p¿=¿0.003) were lower in patients with maculopathy. Multivariate logistic regression modelling was used to control for confounding. For retinopathy severity, a unit increase in eGDR or ISS (representing lower IR) was associated with a 50% decrease in odds of moderate-NPDR or worse (eGDR OR 0.5, 95%CI 0.32¿0.77, p¿=¿0.002; ISS OR 0.49, 95%CI 0.29¿0.84, p¿=¿0.01). A unit increase in eGDR or ISS was associated with a 46¿56% decrease in odds of maculopathy (eGDR OR 0.54, 95%CI 0.37¿0.81, p¿=¿0.003; ISS OR 0.44, 95%CI 0.22¿0.88, p¿=¿0.02). Conclusions IR correlates with more severe retinopathy in young adults with Type 1¿DM. This is the first description of a correlation between IR and maculopathy in Type 1¿DM, warranting further evaluation. Prospective studies examining whether reducing IR can improve microvascular complications are required.

DOI 10.1016/j.diabres.2017.06.022
Co-authors John Attia
2016 Rowe CW, Murray K, Woods A, Gupta S, Smith R, Wynne K, 'Management of metastatic thyroid cancer in pregnancy: risk and uncertainty', ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, (2016)
DOI 10.1530/EDM-16-0071
Co-authors Roger Smith
2016 Rowe CW, Bendinelli C, McGrath S, 'Charting a course through the CEAs: diagnosis and management of medullary thyroid cancer', Clinical Endocrinology, 85 340-343 (2016) [C3]
DOI 10.1111/cen.13114
Show 5 more journal articles

Conference (20 outputs)

Year Citation Altmetrics Link
2018 Rowe C, Dill T, Clarke M, Paul J, Gedye C, King S, Hondermarck H, 'A methodology for validating automated digital whole-slide analysis of immunohistochemical biomarkers using open source software (QuPath).', Newcastle, Australia (2018)
Co-authors Jonathan Paul, Craig Gedye, Hubert Hondermarck
2018 Kuehn J, Rowe CW, Amico F, Ward A, Bendinelli C, 'Management of¿an intrathyroidal cystic parathyroid gland¿with post-traumatic haemorrhagic transformation¿causing¿acute airway compromise', Adelaide, Australia (2018)
2018 Croker E, Chew C, Weigner J, Bendinelli C, McGrath S, Rowe CW, 'The whole is greater than the sum of its parts: synthesised triple-assessment of thyroid nodules optimises pre-operative risk-stratification.', Adeladie (2018)
2018 Rowe CW, Dill T, Faulkner S, Griffin N, Jobling P, King S, et al., 'Increased nerve density around papillary thyroid cancers and primary thyroid cancers with nodal metastases.', Adelaide (2018)
Co-authors Hubert Hondermarck, Craig Gedye, Jonathan Paul, Phillip Jobling, Roger Smith
2018 Pradeepan S, Pullen SJ, Viljevac N, Murdoch T, Bone E, Stormer J, et al., 'VLED is an effective real-life treatment for severe complex obesity, and improves obstructive sleep apnoea', JOURNAL OF SLEEP RESEARCH, Brisbane, AUSTRALIA (2018)
Co-authors Surinder Baines
2018 Faulkner S, Rowe CW, Gaom F, Griffin N, Walker MM, Denham J, et al., 'Nerve Dependence in Cancer', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Co-authors Marjorie Walker, Phillip Jobling, Sam Faulkner, Jim Denham, Hubert Hondermarck
2018 Gao F, Griffin N, Faulkner S, Rowe CW, Williams L, Roselli S, Thorne RF, 'The Neurotrophic Tyrosine Kinase Receptor TrkA and Its Ligand NGF are Increased in Squamous Cell Carcinomas of the Lung', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Co-authors Sam Faulkner, Rick Thorne
2018 Griffin N, Hondermarck H, Gao F, Faulkner S, Jobling P, Rowe CW, 'Neurotrophic Growth Factors and Their Receptors as Novel Therapeutic Targets in Esophageal Cancer', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Co-authors Sam Faulkner, Phillip Jobling, Hubert Hondermarck
2018 Rowe C, Dill T, King S, Gedye C, Paul J, Tolosa JM, Smith R, 'Thyroid cancers resected in patients with concurrent TSH-receptor stimulation have higher levels of sodium-iodide symporter (NIS) expression', CLINICAL ENDOCRINOLOGY, Perth, AUSTRALIA (2018)
Co-authors Jonathan Paul, Roger Smith, Craig Gedye
2017 Marlow A, Rowe C, Anderson D, Wynne K, King BR, Smart CE, 'Children and young adults with type 1 diabetes are more overweight and obese than reference populations, and this worsens with age', Tasmania (2017)
Co-authors Bruce King, Carmel Smart
2017 Croker E, Tan HLE, Rowe C, 'Diabetic ketoacidosis (DKA) in patients on maintenance dialysis: case series and literature review', Perth, Western Australia (2017)
2017 Rowe C, Tolosa Gonzalez JT, Faulkner S, Paul JW, Gedye C, McGrath S, et al., 'The precursor for nerve growth factor (proNGF) is detectable in the rinse of fine needle aspiration biopsy of thyroid cancer', Boston, Massachussetts (2017)
Co-authors Roger Smith, Hubert Hondermarck, Jonathan Paul, Craig Gedye
2016 Faulkner S, Jobling P, Rowe C, Oldmeadow C, Roselli S, Thorne R, et al., 'CLINICOPATHOLOGICAL SIGNIFICANCE OF PRONGF RECEPTORS IN THYROID CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
Co-authors John Attia, Marjorie Walker, Hubert Hondermarck, Rick Thorne, Phillip Jobling, Christopher Oldmeadow
2016 Rowe C, Wynne K, Acharya SA, 'High rates of obesity in young adults with type 1 diabetes.', Gold Coast (2016)
2016 Rowe C, Pain O, Ronthal R, Buckmaster C, Morrison S, Wynne K, 'Betamethasone leads to acute hyperglycaemia in women with GDM.', Gold Coast (2016)
2015 Rowe C, McGrath S, Smith R, 'Response of TSH-Secreting Pituitary Tumours to Somatostatin Analogues in Five Patients', San Diego, California (2015)
DOI 10.1210/endo-meetings.2015.BCHVD.11.SAT-256
Co-authors Roger Smith
2015 Rowe C, mcgrath S, 'Parathyroid Ultrasound As Screening Tool for Familial Hypocalciuric Hypercalcemia', San Diego, California (2015)
DOI 10.1210/endo-meetings.2015.BCHVD.11.SAT-256
2015 Rowe C, Wynne K, Luu J, Quach T, Jackel D, Perry L, Acharya S, 'Emergency Department (ED) utilisation in young adults with type 1 diabetes (T1D) under care of a tertiary clinic.', Adelaide (2015)
Co-authors Lin Perry
2014 Rowe C, McGrath SA, 'Pre-operative localisation of parathyroid adenoma with ultrasound and sestamibi scintigraphy in primary hyperparathyroidism ¿ review of single centre experience.', Melbourne, Australia (2014)
2013 Rowe C, Joshi T, Wynne K, 'Remembering Halsted ¿Mediastinal Mass Complicating Graves¿ disease', Madrid, Spain (2013)
Show 17 more conferences
Edit

Grants and Funding

Summary

Number of grants 5
Total funding $472,528

Click on a grant title below to expand the full details for that specific grant.


20181 grants / $397,528

Hunter Cancer Biobank$397,528

Funding body: NSW Health Pathology - Pathology North

Funding body NSW Health Pathology - Pathology North
Project Team Professor Marjorie Walker, Laureate Professor Rodney Scott, Conjoint Professor Stephen Ackland, Mrs Susan Goode, Associate Professor Pradeep Tanwar, Doctor Nikki Verrills, Professor Hubert Hondermarck, Doctor Simon King, Mr Ricardo Vilain, Associate Professor Nikola Bowden, Doctor Kelly Kiejda, Associate Professor Simon Keely, Doctor Christopher Rowe
Scheme Research Grant
Role Investigator
Funding Start 2018
Funding Finish 2019
GNo G1800704
Type Of Funding C2220 - Aust StateTerritoryLocal - Other
Category 2220
UON Y

20171 grants / $15,000

Hunter Cancer Research Alliance (HCRA)$15,000

Funding body: Hunter Cancer Research Alliance (HCRA)

Funding body Hunter Cancer Research Alliance (HCRA)
Project Team

Christopher Rowe, Hubert Hondermarck, Roger Smith, Shaun McGrath, Simon King, Marjorie Walker, John Attia

Scheme HCRA Implementation Flagship program
Role Lead
Funding Start 2017
Funding Finish 2017
GNo
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON N

20162 grants / $40,000

AVANT Doctors in Training Scholarship$25,000

Funding body: AVANT Mutual Group

Funding body AVANT Mutual Group
Project Team

Christopher Rowe, Jonathan Paul, Jorge Tolosa, Roger Smith

Scheme Doctors in Training Scholarship Scheme
Role Lead
Funding Start 2016
Funding Finish 2016
GNo
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON N

Hunter New England Clinical Research Fellowship$15,000

Funding body: Hunter New England Health

Funding body Hunter New England Health
Project Team

Christopher Rowe

Scheme Clinical Research Fellowship
Role Lead
Funding Start 2016
Funding Finish 2018
GNo
Type Of Funding Other Public Sector - State
Category 2OPS
UON N

20151 grants / $20,000

NewDIAB: Understanding Type 1 Diabetes in Newcastle$20,000

Funding body: John Hunter Charitable Trust

Funding body John Hunter Charitable Trust
Project Team

Christopher Rowe, Shamasunder Acharya, Lin Perry, Katie Wynne

Scheme John Hunter Charitable Trust Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo
Type Of Funding Other Public Sector - State
Category 2OPS
UON N
Edit

Dr Christopher Rowe

Position

Conjoint Lecturer
School of Medicine and Public Health
Faculty of Health and Medicine

Contact Details

Email christopher.w.rowe@newcastle.edu.au
Link Twitter
Edit